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Mitochondria are key organelles that have an essential role in the life and death of cells. They derive from ancient Gram-negative bacteria similar to Rickettsia prowazekii, which began an endosymbiotic process with progenitors of eukaryotic cells more than 2 billion years ago 1 . Mitochondria have retained the structure of these bacteria; they have a highly permeable outer membrane and an inner membrane that is impermeable to most solutes and has several introflexions, named cristae 2 . Most importantly, mitochondria contain their own mitochondrial (mt)DNA, which is a relic of the ancestral endosymbiont genome and resembles prokaryotic DNA. The mitochondrial genome is composed of a single double-stranded circular loop that lacks introns, is not organized into chromatin and uses a different genetic code from that of eukaryotic cells 3 . mtDNA is present in multiple copies per mitochondrion, and transmission of mtDNA-linked traits does not follow classical Mendelian rules 4 (TABLE 1) . mtDNA encodes 37 genes, including 13 structural subunits of the mitochondrial respiratory chain. Proteins encoded by mtDNA represent only a small fraction of the total mitochondrial proteome; the majority of mitochondrial proteins are synthesized in the cytosol and imported into mitochondria via specialized systems 5 .
The most important function of mitochondria is the generation of ATP through oxidative phosphorylation. They are also the site of essential metabolic pathways (including pyrimidine and haem biosynthesis as well as specific reactions of the urea cycle and the β-oxidation pathway) and they have key roles in thermogenesis, calcium homeostasis and control of the intrinsic apoptotic pathway 6 . Mitochondria are highly dynamic organelles; a complex mechanism of fusion and fission processes regulates the remodeling of cristae, which are essential for cytochrome c release and for the initiation of apoptosis 7 . They also have an essential role in tissue injury and repair processes, and have been implicated in various types of renal disorders, both inherited and acquired. In this Review we discuss the main types of mitochondrial cyto pathies that can result in renal disease as well as the role of mitochondrial dysfunction in acute kidney injury (AKI).
The mitochondrial respiratory chain
The mitochondrial respiratory chain is comprised of five enzymatic complexes and two electron carriers: coenzyme Q 10 (CoQ 10 ) and cytochrome c. Complexes I, II, III and IV transfer electrons from high-energy Abstract | Mitochondria are increasingly recognized as key players in genetic and acquired renal diseases. Most mitochondrial cytopathies that cause renal symptoms are characterized by tubular defects, but glomerular, tubulointerstitial and cystic diseases have also been described. For example, defects in coenzyme Q 10 (CoQ 10 ) biosynthesis and the mitochondrial DNA 3243 A>G mutation are important causes of focal segmental glomerulosclerosis in children and in adults, respectively. Although they sometimes present with isolated renal findings, mitochondrial diseases are frequently associated with symptoms related to central nervous system and neuromuscular involvement. They can result from mutations in nuclear genes that are inherited according to classic Mendelian rules or from mutations in mitochondrial DNA, which are transmitted according to more complex rules of mitochondrial genetics. Diagnosis of mitochondrial disorders involves clinical characterization of patients in combination with biochemical and genetic analyses.
In particular, prompt diagnosis of CoQ 10 biosynthesis defects is imperative because of their potentially reversible nature. In acute kidney injury (AKI), mitochondrial dysfunction contributes to the physiopathology of tissue injury, whereas mitochondrial biogenesis has an important role in the recovery of renal function. Potential therapies that target mitochondrial dysfunction or promote mitochondrial regeneration are being developed to limit renal damage during AKI and promote repair of injured tissue.
compounds generated by the reactions of the Krebs cycle (that is, NADH and FADH 2 ), to molecular oxygen, and utilize the energy produced by these reactions to transfer protons from the mitochondrial matrix to the inter membrane space. These processes create an electrochemical gradient that is used by ATP synthase (also known as complex V) to synthesize ATP (FIG. 1) . The respiratory chain complexes I, III and IV assemble to form supercomplexes, which optimize electron flow and minimize the formation of reactive oxygen species (ROS) 8 . With the exception of complex II, which contains only nuclear (n)DNA-encoded subunits, the respiratory chain complexes are comprised of both mtDNA-encoded and nDNA-encoded subunits. Biogenesis of the respiratory chain also requires a large set of ancillary genes, which are encoded by nDNA. These assembly factors are necessary to import and direct structural subunits to the mitochondrial inner membrane, to stabilize assembly intermediates, and to synthesize and insert prosthetic groups into the holoenzymes 9 . A large number of other nuclear gene products are required for the replication and main tenance of the mitochondrial genome, transcription and processing of mitochondrial RNA species, and synthesis of mitochondrial proteins 10 (FIG. 2) .
The electron carrier CoQ 10 is a small lipophilic molecule comprising a quinone group and an isoprene tail. In the respiratory chain, coenzyme Q shuttles electrons from complexes I and II to complex III. CoQ 10 is also a key antioxidant, a modulator of apoptosis, and a cofactor for several other dehydrogenases. Biosynthesis of CoQ 10 requires at least 13 proteins (encoded by nuclear COQ genes) 11 , which are assembled into a multi-enzyme complex localized in the mitochondrial matrix 12 . Cytochrome c is synthesized in the cytosol, imported by a non-canonical mechanism into the mitochondrial inter membrane space and covalently bound to a haem group by holocytochrome c-type synthase. 13 The main role of cytochrome c is the transfer of electrons from complex III to complex IV of the respiratory chain, but this small protein is also an essential component of the intrinsic apoptotic pathway.
Genetic mitochondrial defects
Mitochondrial dysfunction is a common finding in many pathological conditions and might be the direct consequence of a specific genetic defect or the result of a variety of environmental noxae. Although in principle, the term 'mitochondrial disorder' should be used to indicate any defect affecting mitochondrial enzymes or structural proteins, in clinical practice this term is generally used to indicate defects that directly or indirectly affect mito chondrial oxidative phosphorylation 14 . Genetic diseases involving oxidative phosphorylation can be caused by defects in mtDNA (with maternal inheritance or through de novo mutations) or in nDNA (associated with classic Mendelian genetics; TABLE 2) . A third group of disorders includes mtDNA anomalies that are secondary to defects in nuclear genes controlling mtDNA maintenance 10 . Even if these disorders are associated with abnormalities in mtDNA, they are transmitted as autosomal dominant or recessive diseases 10 . Disease-causing mutations that result in defects in oxidative phosphorylation have been reported in >100 genes 15 . Although each individual defect is rare, the overall prevalence of mitochondrial disorders in the general population is probably greater than 1 in 5,000 (REF. 16 ).
In general, mtDNA mutations are heteroplasmic, whereas polymorphisms are homoplasmic (that is, they affect all mitochondrial genomes in an individual). A few examples of homoplasmic mutations also exist, such as the three common mutations that are associated with Leber hereditary optic neuropathy 17 and the mtDNA 1555A>G mutation in the 12S rRNA gene, which causes deafness after exposure to aminoglycosides 18 .
Key points
• Healthy mitochondria are essential for normal kidney function; mitochondrial cytopathies can result in renal disease and mitochondrial damage has a role in the pathophysiology of acute kidney injury (AKI) • Although mitochondrial diseases are characterized by maternal inheritance, many mitochondrial disorders are caused by mutations in nuclear genes and are inherited according to classic Mendelian rules • Most mitochondrial diseases with kidney involvement cause tubular defects; however, mutations in the coenzyme Q 10 biosynthesis pathway and the mtDNA 3243 A>G mutation primarily cause glomerular disease • Diagnosis of genetic mitochondrial disorders increasingly relies on new sequencing techniques, but thorough biochemical and clinical characterization of patients is essential to guide these analyses • In AKI, mitochondrial dysfunction precedes and participates in the physiopathology of tissue damage; mitochondrial biogenesis might represent a crucial step in the recovery phase • Potential therapies that target mitochondrial dynamics, mitophagy and/or mitochondrial biogenesis might limit renal damage during AKI and promote recovery of kidney function These mutations usually have a fairly mild phenotype with selective tissue involvement (either the optic nerve or the cochlea) and their expression is modulated by specific mtDNA haplogroups, nuclear background and epigenetic factors 18 . As complete disruption of oxidative phosphory lation is not compatible with life, residual activity is always present, either because mutations are hypo morphic 19 or redundancy in the system enables a minimal number of functional complexes to be assembled. In the case of mtDNA, heteroplasmy ensures that a small amount of wild-type mitochondrial genome is always expressed, enabling the synthesis of a minimal amount of functional respiratory chain complexes to sustain extrauterine life. Notably, cells with high turnover (such as haematopoietic cell precursors) express lower levels of mutated mtDNA than those with low turnover (such as skeletal muscle and possibly renal cells) as a result of the natural selection of cells with higher percentages of wild-type mtDNA, which replicate more efficiently 20 . Renal disease has been reported in patients with genetic defects involving assembly factors, CoQ 10 biosynthesis, mtDNA translation and mtDNA maintenance (TABLE 3) .
Clinical features of mitochondrial diseases
In general, defects in oxidative phosphorylation produce two major effects: a reduction in ATP production and an increase in ROS production. A direct relationship between the magnitudes of these effects is not always present; for example, mild CoQ 10 deficiency can result in a substantial increase in ROS production without significantly impairing ATP production, whereas severe CoQ 10 deficiency causes an important bioenergetic defect without a substantial increase in ROS production 21 . Defects in electron carriers also affect apoptosis because cytochrome c and CoQ 10 have important roles in this process. CoQ 10 is a modulator of the mitochondrial permeability transition pore and acts as an anti apoptotic factor, whereas mutations in cytochrome c cause deregulation of apoptosis, which is more clinically relevant than the associated bioenergetic defect [21] [22] [23] . Not surprisingly, the tissues that are most severely affected by defects in oxidative phosphorylation are those that are most reliant on aerobic metabolism for ATP production, such as the central nervous system and skeletal muscle. The majority of mitochondrial dis orders, therefore, present with some degree of encephalomyopathy 10 . However, given the ubiquitous distribution of mitochondria, virtually all tissues and organs might be affected by mitochondrial diseases (TABLE 4) .
In the kidneys, mitochondrial disorders can result in various forms of tubulopathies, tubulointerstitial nephritis, cystic renal disease or glomerular disease, most commonly focal segmental glomerulosclerosis (FSGS) 20 . Renal symptoms are rarely isolated and commonly form part of a multisystemic disorder. Exceptions include some mtDNA mutations and some cases of CoQ 10 deficiency in which renal dysfunction might be the only clinical manifestation at presentation 24 . In general, the coexistence of neuromuscular symptoms and renal defects should raise suspicion of a mitochondrial defect 25 . Some symptoms, such as sensorineural deafness or cardiomyopathy, might remain subclinical and require systematic testing. Specific skin and hair lesions have also been described 26 . The first symptoms of mitochondrial defects develop within the first weeks of life in approximately one-third of patients; more than 80% of patients are symptomatic by the age of 2 years 27 .
Renal tubular disorders
After the brain, the kidneys have the highest oxygen consumption per dry weight of tissue, owing to the intense reabsorption and excretion processes that occur in the renal tubules, particularly in cells of the proximal tubule, distal convoluted tubule and connecting segments, which are very rich in mitochondria. Most of the chemical gradients necessary to reabsorb and excrete solutes from the crude glomerular filtrate arise from the basolateral Na-K ATPase. In intact kidneys, approximately 1 mmol of oxygen is estimated to be required for the reabsorption of 20-30 mEq of sodium 28, 29 . In addition to glucose, the kidney oxidizes fatty acids and amino acids to meet this constant metabolic demand.
Unsurprisingly, many mitochondrial disorders are characterized by various degrees of tubular dysfunction. The most severe form of tubulopathy is complete Fanconi syndrome with low-molecular-weight proteinuria, reflecting global dysfunction of the proximal epithelial cells, which can be associated with more distal tubular defects 20, 27, [30] [31] [32] [33] [34] [35] [36] . Fanconi syndrome has also been reported in children with specific mitochondrial syndromes, including Kearns-Sayre syndrome, Pearson syndrome, Leigh encephalopathy and CoQ 10 deficiency 20, 27, 30, 31, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . More frequently, patients present with partial defects, including isolated renal tubular acidosis (RTA), aminoaciduria, glycosuria or a combination of the above 20, 27, 45, [47] [48] [49] [50] [51] . In some children, a Bartter-like phenotype has been reported 52, 53 . Some patients might also present with isolated hyper magnesuria 20 . Tubular defects are frequently not recognized because their clinical manifestations are often mild or overshadowed by more severe neurological symptoms. In a systematic study of 42 patients with mitochondrial disorders, half had renal tubular dysfunction, but only eight had overt disease, suggesting that the prevalence of renal involvement in mitochondrial cytopathies is underestimated 51 . Mutations involving both nuclear and mitochondrial genes have been described to cause tubular defects. In general, consistent phenotypes that link mutations in a given gene to a specific tubular defect have not been identified 20 . Some mutations do, however, tend to be characterized more frequently by certain renal phenotypes; for example, mutations in BCS1L, UQCC2 or FBXL4, which are involved in oxidative phosphorylation, frequently cause proximal renal tubular acidosis 47, 48 . A homo zygous p.Ser78Gly mutation in BCS1L produces a specific clinical phenotype called GRACILE syndrome, which is characterized by intrauterine growth retardation, fulminant lactic acidosis, aminoaciduria and liver haemo siderosis, and is usually fatal in the neonatal period 54 . This syndrome is found almost exclusively in Finnish patients.
To date, two distinct familial mitochondrial tubular disorders have been identified. Mutations in the mitochondrial isoleucine tRNA gene (tRNA Ile or MT-TI) that involve a critical nucleotide for codon-anticodon recognition have been associated with mitochondrial hypomagnesaemia in a large white kindred 55 . Symptoms segregated in the family following a maternal dominance modality and included at least one of the following: hypo magnesaemia, hypercholesterolaemia or hypertension. Serum Mg 2+ levels were low in half of the family members in the maternal lineage and were associated with increased urinary Mg 2+ excretion and decreased urinary Ca 2+ excretion, suggesting a specific defect of the distal convoluted tubule 55 . The mechanisms that underlie Mg 2+ losses in these patients are not fully understood; however, cells of the distal convoluted tubule have very high energy consumption 56 and Mg 2+ reabsorption in this segment requires ATP-dependent Na + reabsorption 55, [57] [58] [59] . A second large family with autosomal dominant Fanconi syndrome characterized by prominent renal bicarbonate and phosphate losses was found to carry mutations in EHHADH 60 . The encoded protein, peroxisomal bifunctional enzyme, is involved in fatty acid oxidation and is primarily expressed in peroxisomes along the terminal segments of the proximal tubule. The mutation that segregates with disease in this family causes mistargeting of the protein to mitochondria, resulting in impaired mitochondrial oxidative phosphorylation with a dominant-negative effect. The latter finding is further substantiated by the absence of Fanconi syndrome in Ehhadh-knockout mice 60 .
Glomerular diseases
Podocytes are highly differentiated cells with limited replicative capacity. They are a major component of the glomerular filtration barrier, support the other capillary components in counteracting endocapillary pressure, synthesize major cytoskeletal proteins and extracellular matrix components, and have several immunological roles 61 . To maintain all of these functions, podocytes are particularly dependent on energy and are rich in mitochondria. Impairment of oxidative phosphory lation in podocytes results in excessive generation of ROS and in functional and structural alterations, resulting in disruption of the glomerular filtration barrier, proteinuria and ultimately the development of glomerular sclerotic lesions 62, 63 . Podocyte mitochondrial dysfunctions ; complex II is spared, as only nuclear genes encode this complex • Many point mutations affect genes that encode tRNAs or rRNAs • The most frequent gross rearrangement is the recurrent 4,977 base pair 'common' deletion 142 • The renal phenotype is usually tubulopathy; glomerular defects are associated with the mtDNA 3243 A>G mutation Structural subunits Mutations in mtDNA-encoded structural subunits usually cause defects in individual respiratory chain complexes nDNA
Assembly factors
• Assembly factors are not part of the respiratory chain, but are necessary for its biogenesis; mutations in genes that encode assembly factors are usually referred to as 'indirect hits' • Some assembly factors are required for specific steps in the biogenesis of individual complexes (for example COX10 encodes a farnesyltransferase that is involved in the biosynthesis of the heme group of complex IV ; therefore, a reduction in CoQ 10 levels does not necessarily indicate a mutation in a COQ gene • Secondary forms of CoQ 10 deficiency are probably much more frequent than primary forms • Mutations in cytochrome c are transmitted as autosomal dominant traits and associated with familial thrombocytopenia; the disease pathogenesis results from deregulation of apoptosis rather than the bioenergetic defect
Mitochondrial dynamics
• The most common defects in genes that control mitochondrial dynamics involve the profusion proteins OPA1 and mitofusin-2
• In addition to promoting mitochondrial fusion, OPA1 is essential for the control of cristae remodelling and the formation of supercomplexes 145 , which increase the efficiency of oxidative phosphorylation • Mitofusin-2 tethers mitochondria to the endoplasmic reticulum; this process is probably important for calcium metabolism 146 
Mitochondrial protein synthesis
• Genes that are involved in mitochondrial protein synthesis include those that encode aminoacyl-tRNA synthases, mitochondrial ribosomal proteins, elongation factors, proteins that are involved in the maturation of mRNAs and tRNAs, and other components of the translation machinery
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• Mutations in these genes typically result in combined defects that spare complex II mtDNA maintenance
• Mutations in genes that encode proteins involved in mtDNA replication or nucleotide metabolism cause secondary mtDNA defects, including depletion (reduction in copy number), multiple deletions (resulting in the tissue-specific presence of mtDNA species with various types of gross deletions) and specific point mutations 147 • Defects in mtDNA maintenance are usually associated with combined deficiencies • Some defects alter the lipid milieu of the mitochondrial inner membrane and indirectly impair oxidative phosphorylation 15 ; for example, TAZ mutations result in Barth syndrome, which is characterized by abnormal cardiolipin metabolism • OPA1 and mitofusin-2 are also required for mtDNA maintenance and their deficiencies cause mtDNA depletion by unclear mechanisms 145 Structural subunits Nuclear gene defects might directly involve structural subunits of individual complexes, most commonly complex I CoQ 10 , coenzyme Q 10 ; mRNA, messenger RNA; mtDNA, mitochondrial DNA; nDNA, nuclear DNA; OPA1, optic atrophy 1 (also known as dynamin-like 120 kDa protein, mitochondrial); tRNA, transfer RNA.
can be acquired, such as in diabetic nephropathy 64 and other chronic renal conditions 65, 66 , or caused by genetic defects in mtDNA or nDNA. In addition to sporadic cases of glomerulopathies secondary to mutations in genes that encode mitochondrial proteins 20 , two major glomerular diseases have been identified: mitochondrial cytopathies secondary to genetic defects in the CoQ 10 biosynthesis pathway and those that are caused by the mtDNA 3243 A>G mutation in the tRNA Leu(UUR) gene.
CoQ 10 biosynthesis defects
Glomerular involvement in these disorders can be isolated or occur as part of a multisystemic disease with a variable age of onset. In most cases, renal involvement is characterized by steroid-resistant proteinuria or nephrotic syndrome with or without haematuria, which usually progresses to chronic renal failure, and FSGS lesions in renal biopsy samples. High numbers of abnormal mitochondria in the cytoplasm of podocytes might sometimes be visible on electron microscopy (FIG. 3) . Diseases resulting from defects in CoQ 10 biosynthesis are receiving increasing attention as a growing number of potentially treatable defects are recognized. These diseases are characterized by broad molecular and clinical heterogeneity, which is related to the large number of enzymes involved in CoQ 10 biosynthesis and the possibility of redundancy in different organs. The clinical relevance of this group of mitochondrial cytopathies is related to their response to oral supplementation with CoQ 10 (REFS 67-69), a treatment that is unparalleled in other mitochondrial diseases. Early diagnosis of affected patients might prevent the development of irreversible neurological lesions and reverse the renal phenotype 67 . Genetic defects that affect CoQ 10 synthesis result in mitochondrial dysfunction and excessive production of ROS, which damage and ultimately cause apoptosis of podocytes. Interestingly, patients with idiopathic FSGS can have partial CoQ 10 COQ2. The first genetic defect that was identified in patients with primary CoQ 10 deficiency was a mutation in COQ2, which encodes 4-hydroxybenzoatepolyprenyl transferase, the enzyme that catalyses the second step in the mitochondrial CoQ 10 biosynthetic pathway 71 . To date, COQ2 mutations have been reported in 15 children from 10 unrelated families; 11 of these patients had glomerular involvement [74] [75] [76] [77] [78] . SRNS usually developed within the first year of life or in the neo natal period, and often represented the first symptom of the disease, with or without neurologic symptoms. However, not all patients with COQ2 mutations develop renal lesions 79 and some show renal involvement later in the course of their disease 78 . Various histologic lesions have been reported; in most cases the renal histology showed FSGS, including one case of collapsing glom erulopathy, but crescentic glomerulonephritis or mild mesangial proliferation have also been reported 75 . On electron microscopy, podocytes appear swollen and packed with abnormal mitochondria 75 (FIG. 3) . The nephrotic syndrome is characterized by a rapid decline in renal function that does not recur after kidney transplantation. Prompt treatment with high doses of CoQ 10 (30 mg/kg) has been shown to halt the progression of the disease, substantially improve proteinuria and reverse the clinical manifestations related to nephrotic syndrome 67 .
PDSS1 and PDSS2. PDSS2 encodes a subunit of the enzyme required for synthesis of the decaprenyl tail of CoQ 10 . In humans, the active form of this enzyme forms a heterotetramer comprising two PDSS1 and two PDSS2 units. To date, PDSS2 mutations have been identified in four patients with glomerular mitochondrial cyto pathies associated with CoQ 10 deficiency from two unrelated families 72, 80 . The first family, with three affected siblings, was originally described in 2006 (REF. 81 ). All three children presented with progressive encephalopathy and SRNS; two children underwent successful renal transplantation at the ages of 8 years and 9 years, whereas the third child died at 8 years of age as a consequence of rapid neurological deterioration. Treatment with oral CoQ 10 (5 mg/kg per day) improved the neuro logic symptoms in the surviving children over 3 years of follow-up. In the second family, the patient presented at 3 months of age with seizures and hypotonia. He sub sequently developed cortical blindness and nephrotic syndrome and died at 8 months of age because of severe refractory focal status epilepticus 72 . His brain MRI was compatible with Leigh syndrome. From 3 months of age, this child was treated with oral CoQ 10 (50 mg per day) with no apparent clinical improvement. The reasons for this lack of response are unclear, but the treatment might have been started too late, when neurological and renal lesions could no longer regress. Two patients with PDSS1 mutations have also been described: the first showed no renal abnormalities 82 whereas the second presented with nephrotic syndrome 73 . A mouse model (kd/kd) harbouring a spontaneous homozygous missense mutation in Pdss2 recapitulates the human renal phenotype and does not show major extra-renal defects 83 . In this model, CoQ 10 supplementation is effective in preventing the onset of renal disease 84 . Interestingly, treatment with the antioxidant and hypolipidemic compound probucol is also effective in preventing renal lesions in these mice 85 . Whether this beneficial effect is related to the antioxidant properties of probucol or whether the drug stimulates CoQ 9 biosynthesis in these animals is unclear. No clinical data on probucol are available, but other antioxidants, such as idebenone (a soluble analogue of CoQ 10 ) do not rescue defects that result in a reduction in the activity of complex II+III 86 and seem to be ineffective at ameliorating symptoms in animal models 80 . The role of ROS in the pathogenesis of glomerulopathy in the kd/kd mouse model is supported by the observation that CoQ 9 deficiency is ubiquitous in these animals, but a significant increase in ROS production is present only in the kidneys, where tissue damage occurs 87 .
COQ6. COQ6 encodes a mono-oxygenase, which cata lyses the C5 hydroxylation step of the quinone ring. Mutations in this gene have been described in 11 patients from five families 68 . All of the affected children presented with SRNS and sensorineural deafness, generally at older ages than those reported for patients with COQ2 mutations. Proteinuria was diagnosed between 0.2 years and 6 years of age (median 1.2 years) and renal function deterior ated rapidly to reach end-stage renal disease (ESRD) between 0.4 years and 9 years of age (median 1.7 years). Five children died at a median age of 5 years. The most frequent renal histological picture (seen in seven patients) was FSGS; diffuse mesangial sclerosis was diagnosed in one biopsy sample. Facial dysmorphism and neurological impairment, including seizures, white matter abnormalities and ataxia, were also reported 68 . Notably the uniformity of the pheno type, and in particular the renal involvement, could reflect selection bias as all of the patients were identified from a SRNS cohort. A yeast complementation study that tested all of the mutated COQ6 alleles reported to date, showed that the defect could be rescued by vanillic acid or dihydroxy benzoic acid (DHB) 19 . These nontoxic analogues of the ring precursor of CoQ 10 are able to bypass the enzymatic defect. DHB has also been shown to be effective in fibroblasts from patients with COQ7 mutations 88 .
ADCK4. ADCK4 is the human orthologue of the yeast COQ8 gene (L. Salviati, unpublished data), which encodes an atypical kinase involved in the regulation of CoQ 10 biosynthesis. In yeast, overexpression of ADCK4 stabilizes the CoQ multienzyme biosynthetic complex, even in the absence of any of its components 89 . Mutations in ADCK4 account for the highest number of patients with renal disease secondary to CoQ 10 biosynthesis defects reported to date: 38 patients from 18 families have been retrospectively described 69, 90 . These patients typically presented with proteinuria and SRNS and most had a renal histological picture . Compared with other CoQ 10 biosynthesis defects, mutations in ADCK4 seem to result in a less severe clinical entity, with a more prominent renal phenotype, higher age at onset of SRNS (usually 10-20 years), slower progression to ESRD and good patient survival owing to the lack of extrarenal manifestations.
The relatively mild phenotype observed in patients with ADCK4 defects is probably related to the fact that the encoded enzyme has a modulatory function without catalytic activity, enabling residual CoQ 10 synthesis even in the complete absence of this protein. In animal models ADCK4 knockout caused reduced podocyte motility in vitro, which could be reversed by adding CoQ 10 to the culture medium 69 . In mice null mutations in other COQ genes prevent CoQ 10 biosynthesis and are not compatible with life 11 . Mutations in ADCK3, a para logue of ADCK4, also causes CoQ 10 deficiency, but the resulting pheno type is completely different from that of ADCK4 mutations and includes cere bellar ataxia and encephalopathy without renal disease 91, 92 . The functional relationship between these two genes requires further study.
Other mutations. Other genetic defects of CoQ 10 biosynthesis, such as mutations in COQ4, COQ9 and COQ7, have not been linked to glomerular disease. Moreover, a patient with a COQ9 mutation had a tubulo pathy without apparent glomerular involvement 44 . The reasons for this phenotypic discrepancy are unclear, but different degrees of destabilization of the CoQ 10 biosynthetic complex by individual mutations might explain some of the variability 93 .
mtDNA 3243 A>G mutation The mtDNA 3243 A>G mutation in the tRNA Leu(UUR) gene is one of the most common mtDNA point mutations. This mutation was initially described in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome, a progressive neurodegenerative disorder that usually presents in children or young adults 94 . Approximately 80% of patients with MELAS syndrome harbour the mtDNA 3243 A>G mutation 95 , but other causative mtDNA mutations have also been reported 43 .
The pheno typic expression of the mtDNA 3243 A>G mutation can be highly variable and causes a wide range of clinical manifestations, including muscle weakness, exercise intolerance, failure to thrive, developmental delay, progressive encephalopathy, migraine, stroke-like episodes, peripheral neuropathy and visual complaints due to ophthalmoplegia. Some patients present with myoclonic epilepsy with ragged red fibres (MERRF) syndrome or maternally inherited diabetes and deafness (MIDD).
Renal involvement is not very common in patients with MELAS syndrome. However, several patients with the mtDNA 3243 A>G mutation have developed proteinuria and renal failure, usually in association with other symptoms (such as diabetes and/or sensorineural hearing loss), but also as an isolated finding, at least at disease onset. The renal disease generally corresponds to a glomerulopathy with proteinuria, which is below the nephrotic range in two-thirds of patients. From the histological standpoint, most patients have FSGS lesions, but three cases of tubulointerstitial nephritis have also been described 20 . Approximately 80% of patients with renal involvement have some degree of deafness, so might be misdiagnosed with Alport syndrome. Overall, patients with the mtDNA 3243 A>G mutation seems to have less overt haematuria than those with Alport syndrome, and their renal biopsy samples do not show the typical ultrastructural findings of this disease. The absence of these features should always raise suspicion of the mitochondrial tRNA Leu mutation. To date more than 30 patients with MELAS syndrome and renal involvement have been described in detail; approximately two-third of these patients were female and their age at diagnosis ranged from 14 years to 50 years 20, 96 . The majority of patients were diagnosed with renal disease in their second or third decade of life and chronic kidney disease was present in half of these cases. Moderate neurologic symptoms were also present in the majority of patients.
A large-scale proteomic analysis of urine samples from adult patients with mitochondrial diseases showed that 75 of 117 participants carried the mtDNA 3243 A>G mutation 97 . Nearly half of the patients with this mutation had albuminuria and/or low-molecularweight proteinuria, indicating that mtDNA 3243 A>G probably represents the most common mitochondrial disorder with renal involvement. Approximately half of the patients with this disorder presented with MIDD, whereas most of the remaining patients presented with MELAS or MERRF syndromes 97 . 
Diagnosis of oxidative phosphorylation defects

Analysis of lactate levels
The diagnosis of defects in oxidative phosphorylation is a complex task that requires a combination of approaches 10 . As a functional respiratory chain is required for the oxidation of lactate (the final product of glycolysis) to carbon dioxide and water, the presence of increased lactate levels in serum or cerebrospinal fluid is an important finding. Such analyses can be integrated with magnetic resonance spectroscopy, which enables estimation of lactate levels in the brain 98 . These levels often fluctuate, however, and might be normal even in the presence of severe defects in oxidative phosphorylation 99 . The lactate-to-pyruvate ratio helps distinguish between oxidative phosphorylation disorders and other defects such as pyruvate dehydrogenase deficiency. Analysis of urinary organic acids might detect lactic aciduria and other abnormalities, such as dicarboxylic aciduria, which is a frequent, albeit nonspecific finding in patients with defects in oxidative phosphorylation 24 . Patients with mitochondrial renal disease often do not have constant hyperlactacidemia but might have elevated urinary lactate excretion. In addition, levels of fibroblast growth factor 21 are increased in patients who have mitochondrial disorders with significant muscle involvement 100 .
Neuroimaging
Neuroimaging often provides important clues to aid diagnosis. Focal lesions in deep grey matter structures, such as the putamen and basal ganglia, are among the most common findings, especially in paediatric patients 101, 102 . Leigh syndrome, which is characterized by focal, bilateral, symmetric lesions involving basal ganglia and the periaqueductal grey matter, represents the effects of severe deficiencies in energy production in the central nervous system in infancy 103 . Older patients might present with stroke-like lesions in non-vascular territories, especially in the parieto-occipital region. These lesions are typical of MELAS syndrome 101 , but are also seen in other defects, including CoQ 10 deficiencies 74 . Lessspecific findings include cortical and cerebellar atrophy, as well as various white matter abnormalities.
Analysis of biopsy samples
Muscle biopsy is still considered the gold standard for diagnosis of oxidative phosphorylation defects 10 . Morphological analyses coupled with histochemical staining enables the detection of COX-deficient fibres and mitochondrial proliferation 104 . A uniform pattern points to a nDNA defect, whereas a mosaic distribution (owing to heteroplasmy) is suggestive of a mtDNA abnormality, which can occur as a result of a mutation in mtDNA or as a secondary effect of a mutation in a nuclear mtDNA maintenance gene. Oil-Red staining might detect lipid accumulation, which is often observed in CoQ 10 deficiencies 105 . Spectrophotometric measurements of enzymatic activities might distinguish between defects involving individual complexes and combined deficiencies. Analysis of the combined activity of complexes II and III, which require CoQ 10 to shuttle electrons to complex III (FIG. 1) , provides an indirect but reliable assessment of CoQ 10 levels 89 . Finally, CoQ 10 concentrations in muscle specimens can be measured using HPLC. Standardized analysis protocols for this technique have been developed and validated 106, 107 . Similar analyses can be performed in cultured primary skin fibroblasts; however, some defects are not expressed in these cells. Cultured fibroblasts also enable functional studies.
In theory, CoQ 10 analyses performed on muscle specimens can also be carried out on renal tissue 75 . Histochemical analyses of renal cortex samples might provide similar information to analyses of muscle specimens 20 ; however, spectrophotometric analyses are more problematic because a surgical biopsy is necessary to obtain a large enough sample.
Next-generation sequencing
Next-generation sequencing approaches are revolutionizing the molecular diagnosis of mitochondrial disorders. The entire mtDNA can now be sequenced rapidly at low cost 108 . In patients with renal involvement, urinary sediment cells could be the optimal material for DNA extraction 109 . Likewise, in cases of nuclear defects, large gene panels or the entire exome can now be analysed 19 .
In the past few years, numerous defects have been characterized at the molecular level using these techniques. Nonetheless, detailed phenotypic characterization of patients remains necessary to restrict the data analysis, which is time consuming and complicated.
Screening for CoQ 10 deficiency. As timely diagnosis is crucial for the success of therapy, the possibility of CoQ 10 deficiency should always be considered in patients with SRNS, particularly infants. No pathognomonic clinical features exist, but SRNS in association with neuro muscular symptoms or deafness should raise the suspicion of CoQ 10 deficiency. Many patients, however, present with SRNS without extrarenal involvement at diagnosis. Moreover, although patients usually present in infancy or early childhood, onset of symptoms might occur later in life. The optimal diagnostic strategy for CoQ 10 deficiency is still debated 110 . Traditional approaches require time and invasive procedures; such delay is not of critical importance in most disorders of oxidative phosphorylation, but might have dramatic consequences in the case of CoQ 10 deficiencies. In principle, all individuals with isolated SRNS should be screened for CoQ 10 deficiency, but performing a skin or muscle biopsy is not always possible. With new tech nological advances and cost reductions, screening using next-generation sequencing and specific gene panels is becoming a valuable diagnostic approach. Even if only 1% of patients with SRNS have CoQ 10 deficiency 111 , the benefits of preventing ESRD and probably also neuro logical deterioration in these patients outweighs the cost of genetic screening, which is routinely performed in most cases. Systematic electron microscopy of renal biopsy samples could also enable rapid identification of many patients, as abnormal mitochondrial proliferation in podocytes is frequently observed 75 .
Mitochondrial dysfunction in acute kidney injury As the renal tubules represent one of the most metabolically active epithelia in the human body, it is unsurprising that AKI -whether septic, ischaemic, or toxic in origin -involves early pathological changes in the mitochondria of the tubular epithelium 112, 113 . These changes include decreased mitochondrial abundance, swelling of individual organelles, and disruption of the otherwise tightly stacked cristae. The proximal tubule is a primary site for mitochondrial disruption in AKI, but changes in the thick ascending limb and distal tubules have also been reported 114 . Evidence for mitochondrial involvement in human AKI was shown in early electron microscopy studies of specimens from patients who had died from septic shock 115 . Subsequent autopsy studies following sepsis and sequential biopsy studies during controlled renal ischaemia (for example, for nephrectomy) revealed similar lesions in mitochondria 116, 117 . Mitochondrial dysfunction in AKI typically accompanies ultrastructural pathology. For example, experimental cisplatin nephrotoxicity induces a decrease in the activity and expression of cytochrome c oxidase in the proximal tubule, but not in the distal nephron segments. This finding is consistent with the clinical observation that proximal tubular manifestations dominate the presentation of platinum-induced renal injury 118 . Comparison of a toxic form of AKI, glycerolinduced rhabdomyolysis, with post-ischaemic AKI showed that both conditions result in widespread loss of mitochondrial respiratory proteins from proximal tubules 119 , whereas experimental sepsis leads to a profound decrease in the expression and activity of multiple enzymatic components of the mitochondrial electron transport chain 112 . Injured mitochondria not only deprive the cell of ATP, but are an important source of molecules that amplify injury, precipitate cell death and induce inflammation (FIG. 4) . ROS released from damaged mitochondria contribute to the oxidative stress widely reported in AKI. Structural disruption of mitochondria also releases cytochrome c, a trigger of apoptosis, as well as mtDNA, which can serve as a proinflammatory danger signal 120 . A highly orchestrated process of mitochondrial biogenesis, replication, and clearance via macroautophagy enables healthy cells to avoid the dangers of mitochondrial injury. Conversely, growing evidence indicates that mitochondria might be a compelling therapeutic target in multiple forms of AKI.
Fatty acids
Although comprehensive discussion of mitochondrial energy metabolism in AKI is beyond the scope of this Review, the roles of fatty acids and ROS need to be highlighted. Fatty acids are the most efficient source of mitochondrial ATP generation, but their intracellular accumulation can result in lipotoxicity. During ischaemia, a mismatch develops between ongoing hydrolysis of membrane phospholipids and reduced clearance of these fatty acids via re-esterification and mitochondrial fatty acid oxidation. This imbalance leads to the accumulation of non-esterified fatty acids (NEFAs), which can act as detergents that weaken the membrane structure, culminating in apop tosis. Biochemical interventions to reduce NEFAs (for example, by applying citric acid cycle substrates) protect freshly isolated proximal tubules from hypoxia-reoxygenation injury and restore normal ATP production [121] [122] [123] . In transgenic mice that overexpress the transcription factor peroxisome proliferator-activated receptor-α, protection against ischaemic AKI is associ ated with restoration of normal fatty acid metabolism 124 . Finally, the sequestration of noxious fatty acids into the storage form of triglycerides might be an endogenous adaptive response to injury. Triglyceride accumulation in cortical and medullary segments of nephrons seems to be a hallmark of diverse renal injuries, ranging from acute obstruction to experimental sepsis and ischaemia-reperfusion injury (IRI) 125, 126 .
Reactive oxygen species
During normal mitochondrial metabolism, a large concentration gradient of hydrogen ions across the inner mitochondrial membrane provides the energy for the phosphorylation of ADP to ATP. When components of the electron transport chain are downregulated, disassembled, spatially displaced or altered, the movement of electrons can become dysregulated, resulting in the generation of excess ROS. Mitochondria seem to be a major source of excess ROS during acute cellular injury as a result of inflammation or ischaemic stress. Although ROS have vital signalling roles in healthy cells, excess levels can lead to catalytic free-radical damage to all classes of macromolecules. Generic antioxidants might have limited therapeutic potential in AKI, but two different classes of mitochondria-targeted antioxidants seem promising in preclinical models. One class of such molecules, an example of which is MitoQ, covalently links the antioxidant ubiquinone to a lipophilic cation that 'locks' the compound into mitochondria 127, 128 . Another therapeutic strategy involves using engineered peptides that localize to the mitochondrion and scavenge local antioxidant species, for example a Szeto-Schiller peptide 129 . Experiments using mitochondria-targeted antioxidants have confirmed that mitochondria are an important source of ROS during various types of renal injury and shown that reduction of mitochondriaderived ROS can ameliorate AKI 130, 131 . These mol ecules are currently being examined in clinical settings of excess mitochondrial ROS generation, such as IRI.
Mitochondrial dynamics
Ischaemic and toxic forms of AKI are characterized by marked mitochondrial fragmentation. The fragmented mitochondria are potential sources of ROS, cytochrome c, mitochondrial DNA and other potentially injurious molecules. Inhibition of mitochondrial fission by genetically or pharmacologically blocking dynaminrelated protein 1 (Drp1) has been shown to protect cultured renal tubular cells from stress-induced apoptosis and attenuate AKI following ischaemia-reperfusion or cisplatin exposure 113 . Experimental pigment nephropathy can also be ameliorated by Drp1 inhibition 132 . Although complementary experiments with gain-of-function mutations remain to be performed, these findings suggest that altered mitochondrial dynamics are a key feature of AKI and a potential therapeutic target. Consistent with this hypothesis, experimental evidence suggests that the NAD-dependent protein deacetylase sirtuin 3 might attenuate cisplatininduced mitochondrial fragmentation and protect against experimental AKI 133 .
Mitophagy
Safe disposal of fragmented mitochondria via mitophagy might protect stressed cells from death and ameliorate AKI. Renal IRI has been shown to induce mitophagy in renal tubules 134 , and mice that lack the autophagy regulator Atg7 show increased sensitivity to cisplatin nephro toxicity 135 . Drugs that induce mitophagy, such as rapamycin, merit further exploration as therapeutic strategies to enhance the clearance of injury-propagating fragmented mitochondria and accelerate recovery after AKI.
Mitochondrial biogenesis
To maintain a steady pool of mitochondria, losses to mitophagy must be replenished by the expansion of mitochondrial mass. An array of nuclear transcription factors and co-activators are involved in mitochondrial biogenesis. The best studied co-activator is peroxisome proliferator-activated receptor-γ co-activator 1-α (PGC-1-α), which is highly expressed in the most metabolically active organs, including the heart, kidney, brains, skeletal muscle and liver 136 . In the kidney PGC-1-α expression reflects the relative distribution of mitochondria; the highest expression is in the cortex, followed by the tubules with much lower levels in the glomerulus 112 . In ischaemic and septic AKI, an initial decrease in PGC-1-α expression is followed by a return to normal levels as organ function recovers, suggesting a role of this co-activator in AKI recovery 112, 119 . Consistent with this hypothesis, specific knockout of Ppargc1a, which encodes PGC-1-α, from the proximal tubule blunted renal recovery following experimental sepsis 112 . Signals from innate inflammatory pathways might result in downregulation of PGC-1-α during infection 137, 138 . Figure 4 | Mitochondrial injury and recovery during acute kidney injury (AKI). Tubular epithelial cells in the proximal tubule and outer medulla are heavily invested with mitochondria in order to generate the ATP necessary for solute transport. Diverse aetiologies of AKI injure the mitochondria, leading to organellar swelling and fragmentation. Injured mitochondria, in turn, release an array of proinflammatory and injurious molecules, such as reactive oxygen species (ROS), which, if unchecked, promote cell death. Experimental findings suggest that recovery from AKI might require the clearance of injured mitochondria through mitophagy and the replenishment of mitochondrial mass through mitochondrial biogenesis, a process mediated by the transcriptional co-activator peroxisome proliferator-activated receptor-γ co-activator 1-α (PGC-1-α). Examples of potential preventive and therapeutic strategies are highlighted in pink boxes. mtDNA, mitochondrial DNA.
Data from gain-of-function experiments also suggest that targeting mitochondrial biogenesis might attenuate renal injury and/or accelerate recovery from AKI. In cultured proximal tubular cells, induction of PGC-1-α after (but not before) oxidant exposure accelerated recovery of mitochondrial function 139 . To identify pharma cological stimulators of mitochondrial bio genesis, Jesinkey et al. screened a large library of small molecules in model cellular systems. One such compound, the β-adrenergic agonist formoterol, stimulated mitochondrial bio genesis, reduced necrosis and improved kidney function in mice that had been subjected to renal IRI 140 . Further studies are required to determine whether PGC-1-α is required for formoterol-dependent renoprotection, and to delineate the under lying mechanisms. However, these findings are promising because they suggest the translational utility of unbiased cell-based drug screens targeting mitochondrial processes to identify agents that might aid recovery from established AKI.
Conclusions
Healthy mitochondria are essential for normal renal health and mutations that directly or indirectly impair mitochondrial function or assembly can cause renal disease. The genetics of mitochondrial disorders is complex and can follow various patterns of inheritance. Although most patients with renal disease resulting from a mitochondrial disorder have a tubulopathy, two well-defined glomerular diseases in patients with mitochondrial cytopathies have been described: FSGS resulting from defects in the CoQ 10 biosynthesis pathway and FSGS secondary to the mtDNA 3243 A>G mutation. These latter diseases are particularly important because defects in CoQ 10 biosynthesis might be rescued by oral CoQ 10 supplementation and renal diseases caused by the mtDNA 3243 A>G mutation are transmitted following a maternal pattern of inheritance and associated with extrarenal symptoms that need to be monitored.
In most cases, however, mitochondrial damage is acquired. Injury to tubular mitochondria represents an early event during AKI. As injured mitochondria release multiple noxious factors, the cellular processes that occur upstream and downstream of this event are of substantial interest. Research into the effects of targeting mitochondrial dynamics, mitophagy and biogenesis has yielded consistent and exciting results that suggest the potential of manipulating these processes to ameliorate AKI. New approaches developed to treat acquired mitochondrial damage might also be potentially beneficial in some genetic mitochondrial disorders. Other alternative strategies, such as pronuclear transfer -a technique for mitochondrial replacement -might also represent potentially valuable approaches in some diseases, but ethical considerations need to be addressed before such techniques can be adopted in clinical practice 141 .
